Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Sodium Oxamate (Oxamic acid sodium salt) is an LDH inhibitor that specifically inhibits LDHA. Sodium Oxamate has antitumor activity and induces cell cycle arrest and apoptosis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 g | In stock | $ 31.00 | |
1 mL * 10 mM (in H2O) | In stock | $ 39.00 |
Description | Sodium Oxamate (Oxamic acid sodium salt) is an LDH inhibitor that specifically inhibits LDHA. Sodium Oxamate has antitumor activity and induces cell cycle arrest and apoptosis. |
In vitro |
METHODS: Human lung cancer cells H1299, A549 and normal human bronchial epithelial cells HBE were treated with Sodium Oxamate (1-100 mmol/L) for 24 h. Cell viability was measured by CCK-8 assay. RESULTS: Sodium Oxamate significantly inhibited the cell viability of H1299 and A549 cells in a dose-dependent manner, with IC50 of 32.13±2.50 and 19.67±1.53 mmol/L, respectively. Sodium Oxamate had almost no effect on HBE cells, with an IC50 of 96.73±7.60 mmol/L. [1]. METHODS: Human lung cancer cells A549 and normal human bronchial epithelial cells HBE were treated with Sodium Oxamate (20-100 mmol/L) for 24 h, and several intracellular biochemical parameters were measured. RESULTS: LDH activity, ATP content and NADPH/NADP ratio were significantly decreased and ROS content was significantly increased in A549 cells after Sodium Oxamate treatment. In contrast, glucose metabolism was less affected, although LDH enzyme was also inhibited in a dose-dependent manner in HBE cells. [2] |
In vivo |
METHODS: To detect the antitumor activity in vivo, Sodium Oxamate (300 mg/kg once a day) and pembrolizumab (10 mg/kg twice a week) were intraperitoneally injected into B-NDG mice carrying human lung cancer tumor H1299 for fifteen days. RESULTS: Both Sodium Oxamate and pembrolizumab significantly delayed tumor growth in monotherapy, and the combination therapy was more effective. [1] METHODS: To explore the potential for the treatment of diabetes, Sodium Oxamate (350-750 mg/kg) was administered intraperitoneally to db/db mice once daily for twelve weeks. RESULTS: Sodium Oxamate treatment reduced body weight gain, blood glucose and HbA1c levels, and improved insulin secretion, pancreatic islet morphology, and insulin sensitivity in db/db mice.Sodium Oxamate improves glycemic control and insulin sensitivity in db/db mice, primarily by inhibiting the production of tissue lactic acid. [3] |
Synonyms | oxamate sodium, Oxamic acid sodium salt, Aminooxoacetic acid sodium salt, SO |
Molecular Weight | 111.03 |
Formula | C2H2NNaO3 |
CAS No. | 565-73-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 16.67mg/ml(150mM), Sonication is recommended.
DMSO: Insoluble
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Sodium Oxamate 565-73-1 Apoptosis Cell Cycle/Checkpoint Metabolism Dehydrogenase CDK Aminooxoacetic acid sodium oxamate sodium Oxamic acid sodium salt Aminooxoacetic acid sodium salt SO Oxamic acid sodium inhibitor inhibit